loratadine has been researched along with Innate Inflammatory Response in 5 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma." | 9.11 | Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005) |
| "We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af ) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma." | 7.72 | Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. ( Bryce, PJ; Geha, R; Oettgen, HC, 2003) |
| "Nasal obstruction is the main symptom in patients with perennial allergic rhinitis." | 6.71 | Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. ( Allen, M; Barberi, S; Ciprandi, G; Cirillo, I; Civardi, E; Marseglia, GL; Vizzaccaro, A, 2005) |
| " In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma." | 5.11 | Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005) |
| "We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af ) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma." | 3.72 | Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. ( Bryce, PJ; Geha, R; Oettgen, HC, 2003) |
| "Nasal obstruction is the main symptom in patients with perennial allergic rhinitis." | 2.71 | Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. ( Allen, M; Barberi, S; Ciprandi, G; Cirillo, I; Civardi, E; Marseglia, GL; Vizzaccaro, A, 2005) |
| "The edema was produced in a dose- and time-dependent manner." | 1.39 | Pharmaco-modulations of induced edema and vascular permeability changes by Vipera lebetina venom: inflammatory mechanisms. ( Laraba-Djebari, F; Sebia-Amrane, F, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Sebia-Amrane, F | 1 |
| Laraba-Djebari, F | 1 |
| Bryce, PJ | 1 |
| Geha, R | 1 |
| Oettgen, HC | 1 |
| Reinartz, SM | 1 |
| Overbeek, SE | 1 |
| Kleinjan, A | 1 |
| van Drunen, CM | 1 |
| Braunstahl, GJ | 1 |
| Hoogsteden, HC | 1 |
| Fokkens, WJ | 1 |
| Ciprandi, G | 1 |
| Cirillo, I | 1 |
| Vizzaccaro, A | 1 |
| Civardi, E | 1 |
| Barberi, S | 1 |
| Allen, M | 1 |
| Marseglia, GL | 1 |
2 trials available for loratadine and Innate Inflammatory Response
| Article | Year |
|---|---|
Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients.
Topics: Adult; Asthma; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Inflammation; Loratadine; Mal | 2005 |
Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study.
Topics: Adolescent; Adult; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists, N | 2005 |
3 other studies available for loratadine and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Pharmaco-modulations of induced edema and vascular permeability changes by Vipera lebetina venom: inflammatory mechanisms.
Topics: Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Capil | 2013 |
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.
Topics: Allergens; Animals; Asthma; Bronchial Hyperreactivity; Cytokines; Disease Models, Animal; Dose-Respo | 2003 |